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Background. Individual randomized trials have suggested that everolimus-eluting stents may have improved clinical outcomes
compared to paclitaxel-eluting stents, but individual trials are underpowered to examine outcomes such as mortality and very
late stent thrombosis. Methods. Medline, Cochrane, and conference proceedings were searched for randomized trials comparing
everolimus versus paclitaxel-eluting stents for percutaneous coronary intervention. Results. 6792 patients were included from 4
randomized controlled trials. Stent thrombosis was reduced with everolimus stents versus paclitaxel stents (0.7% versus 2.3%; OR:
0.32; CI: 0.20–0.51; P<0.00001). The reductions in stent thrombosis were observed in (i) early stent thrombosis (within 30 days)
(0.2% versus 0.9%; OR: 0.24; P = 0.0005), (ii) late (day 31–365) (0.2% versus 0.6%; OR: 0.32; P = 0.01), and (iii) very late stent
thrombosis (>365 days) (0.2% versus 0.8%; OR: 0.34; P = 0.009). The rates of cardiovascular mortality were 1.2% in everolimus
group and 1.6% in paclitaxel group (OR: 0.85; P = 0.43). Patients receiving everolimus-eluting stents had signiﬁcantly lower
myocardial infarction events and target vessel revascularization as compared to paclitaxel-eluting stents. Interpretation. Everolimus
compared to paclitaxel-eluting stents reduced the incidence of early, late, and very late stent thrombosis as well as target vessel
revascularization.
1.Introduction
Bare metal stents (BMSs) were introduced to improve the
acute results of coronary angioplasty and to prevent resteno-
sis compared to balloon angioplasty [1]. The ﬁrst generation
of drug eluting stents (DESs) demonstrated signiﬁcant
reductions in restenosis and target vessel revascularization
(TVR) compared with BMS [2]. However, meta-analyses
of randomized trials have suggested an excess in late stent
thrombosis (ST) for paclitaxel and sirolimus DES compared
to BMS [3].
The ﬁrst Paclitaxel-eluting stent (PES), used widely, was
the Taxus Express stent (Boston Scientiﬁc, Natick, MA,
USA), and this stent was tested against BMS in multiple
randomized trials and demonstrated nearly 50% reduction
in target lesion revascularization (TLR) and TVR. However,
t h e r ew a sa ne x c e s so fv e r yl a t eS T( >1 year) in those
patients who were treated with PES compared to BMS [1].
Subsequently, a 2nd PES stent has been approved, the Taxus
Libert stent´ e, (Boston Scientiﬁc, Natick, MA, USA) which
had the same drug and polymer but had thinner struts
and improved deliverability. The TAXUS ATLAS study [4]
compared outcomes with Taxus Liberte to historical controls
treated with Taxus Express and showed similar outcomes.
The 2nd generation DES, the Xience V Everolimus-
eluting stent (EES) (Abbot Vascular, Santa Clara, CA, USA)
consists of the multilink vision cobalt chromium platform
with a nonerodible polymer and everolimus, a synthetic
derivative of Sirolimus. Individual randomized trials have
suggested reduced rates of myocardial infarction (MI) and
e a r l yS Tw i t ht h eE E Sv e r s u sP E S[ 5–8]. However, what
remains unanswered is if the newer generation Everolimus-
eluting stents reduce the rate of late and very late ST
as well as mortality. A meta-analysis of available trials2 Thrombosis
Table 1: Description of the included trials.
Source
Number of patients
Inclusion criteria Key exclusion criteria Clinical follow-up
duration, months EES PES
Kedhi et al. [6],
2010 897 903 Consecutive patients referred for
elective or emergent PCI Planned major surgery within 30 days 24
Garg et al. [5],
2009 223 77
Ischemia and vessel size
2.5–4.25mm and lesion length
≤28mm
Recent MI, LVEF ≤30%, left main, heavily
calciﬁed lesion, or visible thrombus 48
Stone et al. [7],
2009 669 332
Stable, unstable angina or
inducible ischemia with vessel
2.5–3.75mm diameter and lesion
length ≤28mm
Recent MI, LVEF <30%, LM bifurcation,
by-pass graft, calciﬁcation, and thrombus 36
Stone et al. [8],
2010 2458 1229
Angina or ischemia with vessel
2.5–3.75mm diameter and lesion
length ≤28 mm
Recent MI, LVEF <30%, left main
bifurcation, total occlusion, heavy
calciﬁcation, total occlusion, restenosis, and
visible thrombus, and vein graft PCI
24
Abbreviations: EES, Everolimus-Eluting Stent; PES, Paclitaxel-Eluting Stent; MI, Myocardial Infarction; LVEF, Left Ventricular Ejection Fraction; PCI,
Percutaneous Coronary Intervention.
may allow increased power for important clinical outcomes
that individual trials are not powered to compare such as
mortality and very late ST.
The objective of this meta-analysis was to compare the
eﬃcacy and safety of EES versus PES especially with regards
to the patient important outcomes of ST (early, late, and very
late), cardiovascular death and MI.
2. Methods
2.1. Criteria for Study Selection. We selected randomized
controlled trials that compared the use of EES and PES in
percutaneous coronary intervention (PCI).
2.2. Outcomes and Deﬁnitions. The primary outcomes of
interest was ST, subclassiﬁed as early (within 30 days), late
(31–365 days), and very late (>365 days) and cardiovascular
death. Other outcomes included MI and TVR. ST was
adjudicated according to the criteria for deﬁnite or probable
ST of the Academic Research Consortium [9]. MI was
deﬁnedasatypicalriseandfallinconcentrationsoftroponin
or creatinine kinase-MB with at least one of the following:
ischemic symptoms, development of pathological Q waves,
ischemic electrocardiographic changes, or pathological ﬁnd-
ings of an acute MI in one trial [6]. Also, it was deﬁned
as either as the development of new pathologic Q waves
0.4 seconds or longer in duration in 2 or more contiguous
leads or as an elevation of creatinine phosphokinase levels to
more than 2 times normal with positive levels of creatinine
phosphokinase MB in one trial [7], while it was deﬁned as
an elevation of CK to ≥2 times the upper limit of normal
with elevated CK-MB in the absence or presence of new
pathological Q waves on the electrocardiogram (non-Q- and
Q-wave MI, resp.) in two trials [5, 8].
A composite of safety and eﬃcacy (all-cause mortality,
MI, and TVR) was the primary end point in one trial [6],
while the composite of cardiac death, MI, or ischemia-driven
TVR was the primary end point in 3 trials [5, 7, 8]. ST was
one of the secondary end points in all trials.
In the three trials [6–8], at least 300mg of Aspirin was
administered before catheterization as well as a ≥300mg
oral dose of clopidogrel was recommended before the proce-
dure. In the fourth trial, the periprocedural pharmaceutical
treatment was administrated according to standard hospital
practice without speciﬁcation [5]. Maintenance therapy with
Clopidogrel consisted of a daily dose of 75mg for at least 6
months in two trials [5, 7] and at least 12 months in the
two other trials [6, 8]. Maintenance therapy with Aspirin
consisted of a daily dose of ≥75mg for at least 1 year in one
trial [5] while ≥80mg indeﬁnitely in two trials [7, 8]. In the
fourth trial, patients were maintained on 80mg of aspirin
indeﬁnitely [6]. There was no signiﬁcant diﬀerence between
both groups regarding compliance with antiplatelet therapy
u pt o1y e a rf o l l o w u p .
All trials reported the clinical outcomes of interest from
24-month up to a 4-year follow-up period (Table 1). Routine
follow-up angiography was part of the study protocol in
two trials at 180 days and 8 months, respectively [5, 7]. No
routine follow-up angiography was planned in the other two
trials [6, 8]. Each trial speciﬁed the stent platform that they
used (Table 2).
2.3. Data Sources. We searched PubMed and the Cochrane
Library for randomized controlled trials comparing EES
with the PES in PCI. We limited our search to only the
publications in English language. In addition, we manually
searched the abstracts submitted to the American College of
Cardiology (ACC), the American Heart Association (AHA),
theEuropeanSocietyofCardiology(ESC),andTranscatheter
Therapeutics (TCT) up to May 27, 2011 (Diagram 1). Also,
we contacted trials’ authors for further data as needed.
2.4. Data Collection and Assessment of Quality. Studies
were selected, and data were extracted independently by
2 reviewers (A. Alazzoni and A. Al-Saleh). DisagreementsThrombosis 3
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Figure 1: Data source ﬂow chart diagram.
were resolved by consensus. We recorded the following
clinical and angiographic characteristics, in addition to the
number of participating patients: age, sex, diabetes mellitus,
hypertension, hyperlipidemia, number of target lesions,
location of target lesion, reference-vessel diameter, minimal
luminal diameter, diameter stenosis, and lesion length.
Duration of clinical followup and whether or not a followup
using angiography was done as well as duration of aspirin
and Thienopyridine use were also recorded. All available
data was utilized including full publications, abstracts, and
online late breaking presentations provided by the principal
investigators.
We evaluated the quality of the involved trials using the
Cochrane Collaboration’s tool for assessing risk of bias [10].
In a similar manner to data collection, trials were evaluated
independently by 2 reviewers (A. Alazzoni and A. Al-Saleh).
Disagreements were resolved by consensus.
2.5. Statistical Analysis. All analyses were performed based
on intention-to-treat data. Odds ratios (ORs) with 95%
conﬁdence intervals (CIs) were computed as summary
statistics. The pooled OR was calculated with the Mantel-
Haenszel method for ﬁxed eﬀects [11] and for a sensitivity
analysis with the Mantel-Haenszel method for random
eﬀects. To assess heterogeneity across trials, we used the
Cochran Chi2 test based on the pooled OR by Mantel-
Haenszel. Heterogeneity was also assessed by means of
statistic as proposed by Higgins et al. [12]. Results were
considered statistically signiﬁcant at P ≤ 0.05. There was
no adjustment for multiple comparisons. Statistical analyses
were performed with Review Manager (RevMan) software
version 5.
3. Results
Our search identiﬁed 4 randomized controlled trials
(Figure 1) that compared EESs and PESs use in 6792 patients
during PCI [5–8]. Also, updates regarding all the trials were
found through our manual search of PubMed [13–16].
Follow-up duration was 24 months in two trials [14, 16],
36 months in one trial [15], and 48 months in one trial
[13]( Table 1). The abstracted data represents the longest
available follow-up data.
Overall, the number of patients treated with EES was
4247, while the control arm had 2541 patients who were
treated with PES (Table 1). The mean age of patients is 62.9
inbothgroups.Therewerenosigniﬁcantdiﬀerencesbetween
patientstreatedwiththeEESsandthePESsregardingtherate
of diabetes. The proportion of patients with diabetes ranged
from 17.1% to 32% in the EES group compared with 19% to
32.5%inthePESgroup.Onlyonetrialallowedenrollmentof
patients with STEMI or recent MI [6]. Three trials excluded
patients with vessel diameters <2.5mm [5, 7, 8]. Similarly,
patients assigned to the two drug-eluting stent types did not
diﬀer with respect to the main angiographic characteristics
of the lesions.
3.1. ST. The incidence of ST (deﬁnite and probable) at all
followupswas0.7%(28of4169)amongpatientstreatedwith
the EES and 2.3% (57 of 2498) among patients treated with
the PES (OR: 0.32, 95% CI: 0.20–0.51; P<0.00001), with
no signiﬁcant study heterogeneity (Chi
2 = 3.18; P = 0.36;
I2 = 6%) (Figure 2(a)). For deﬁnite ST, the incidence at all
followupswas0.5%(21of4179)amongpatientstreatedwith
the EES and 1.6% (40 of 2499) among patients treated with
the PES (OR: 0.33, 95% CI: 0.19–0.57; P = 0.0001).
LookingspeciﬁcallyatearlyST(0–30days),theincidence
was 0.2% (8 of 4238) among patients treated with the EES
and 0.9% (23 of 2535) among patients treated with the
PES (OR: 0.24, 95% CI: 0.11–0.54; P = 0.0005), with no
signiﬁcant study heterogeneity (Chi
2 = 3.98; P = 0.26; I2 =
25%) (Figure 2(b)).
Furthermore, the incidence of late ST (31–365 days)
was 0.2% (7 of 4157) among patients treated with the
EES and 0.6% (15 of 2476) among patients treated with
the PES (OR: 0.32, 95% CI: 0.13–0.78; P = 0.01), with
no signiﬁcant study heterogeneity (Chi
2 = 1.98; P = 0.58;
I2 = 0%) (Figure 2(c)). Regarding very late ST (>365 days),
the incidence at all followups was 0.2% (10 of 4175) among
patients treated with the EES and 0.8% (19 of 2498) among
patients treated with the PES (OR: 0.34, 95% CI: 0.15–
0.77; P = 0.009), with no signiﬁcant study heterogeneity
(Chi
2 = 1.45; P = 0.69, I2 = 0%) (Figure 2(d)).
3.2. Death. The incidence of all-cause death at all followups
was 2.5% (106 of 4194) among patients treated with the EES
and 3.2% (80 of 2517) among patients treated with the PES
(OR: 0.8, 95%; CI: 0.59–1.07; P = 0.14). The incidence of
cardiovascular death at all followup was 1.2% (52 of 4186)
among patients treated with the EES and 1.6% (40 of 2511)
among patients treated with the PES (OR: 0.85, 95% CI:
0.56–1.28; P = 0.43), with no signiﬁcant study heterogeneity
(Chi
2 = 4.81; P = 0.19; I2 = 38%) (Figure 3(a)).
3.3. MI. EESs were signiﬁcantly more eﬀective in the reduc-
tion of MI (Figure 3(b)). The incidence of MI at all followup
was 3.0% (126 of 4179) among patients treated with the EES
and 5.6% (140 of 2504) among patients treated with the PES
(OR: 0.56; 95% CI: 0.43–0.72; P<0.00001).Thrombosis 5
8 897 35 903 53.9% 0.22 [0.1, 0.48]
2 195 2 67 4.6% 0.34 [0.05, 2.44]
8 619 5 299 10.4% 0.77 [0.25, 2.37]
10 2458 15 1229 31.1% 0.33 [0.15, 0.74]
Total (95% CI) 4169 2498 100% 0.32 [0.2, 0.51]
Total events 28 57
Test for overall eﬀect: Z = 4.76 (P<0.00001)
Study or subgroup Events Total Events Total
Compare (6)
Spirit II (13)
Spirit III (15)
Spirit IV (16)
Heterogeneity: χ2 = 3.18, df = 3 (P = 0.36); I2 = 6%
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours paclitaxel
Everolimus Paclitaxel
Weight
(a)
Compare (6) 2 897 15 903 55% 0.13 [0.03, 0.58]
Spirit II (5) 0 223 1 77 8.2% 0.11 [0, 2.83]
Spirit III (7) 3 667 0 330 2.5% 3.48 [0.18, 67.6]
Spirit IV (8) 3 2451 7 1225 34.4%
Total events 8 23
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours paclitaxel
Everolimus Paclitaxel
Weight
Total (95% CI)
Test for overall eﬀect: Z = 3.49 (P 0.0005)
Heterogeneity: χ2 = 3.98, df = 3 (P =
=
0.26); I2 = 25%
0.21 [0.06, 0.83]
4238 2535 100% 0.24 [0.11, 0.54]
(b)
0.1 0.2 0.5 1 2 5 10
Compare (6) 3 897 8 903 43.7% 0.38 [0.1, 1.42]
Spirit II (5) 0 223 1 77 12.2% 0.11 [0, 2.83]
Spirit III (7) 3 648 2 315 14.7% 0.73 [0.12, 4.38]
Spirit IV (8) 1 2389 4 1181 29.4% 0.12 [0.01, 1.1]
4157 2476 100% 0.32 [0.13, 0.78]
Total events 7 15
Heterogeneity: χ2 = 1.98, df = 3( P = 0.58
Test for overall eﬀect: Z = 2.52 (P = 0.01) Favours everolimus Favours paclitaxel
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
Everolimus Paclitaxel
Weight
Total (95% CI)
); I2 = 0%
(c)
Compare (14) 3 897 13 903 61.2% 0.23 [0.07, 0.81]
Spirit II (13) 2 193 1 67 7% 0.69 [0.06, 7.75]
Spirit III (7) 2 627 3 299 19.2% 0.32 [0.05, 1.9]
Spirit IV (16) 3 2458 2 1229 12.6% 0.75 [0.13, 4.49]
4175 2498 100% 0.34 [0.15, 0.77]
Total events 10 19
Heterogeneity: χ2 1.45, df = 3( P = 0.69
Test for overall eﬀect: Z =
=
(P = 0.009)
Total (95% CI)
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours faclitaxel
Everolimus Paclitaxel
Weight
); I2 = 0%
2.6
(d)
Figure 2: Odds ratio of stent thrombosis ((a): all, (b): early, (c): late, and (d): very late stent thrombosis) associated with everolimus-eluting
stent versus paclitaxel-eluting stent.6 Thrombosis
1.26 [0.65, 2.46]
0.11 [0.01, 1.08]
0.81 [0.29, 2.26]
0.7 [0.36, 1.36]
Compare (14) 20 897 16 903 32.6%
Spirit II (13) 1 195 3 67 9.3%
Spirit III (15) 10 636 6 312 16.6%
Spirit IV (16) 21 2458 15 1229 41.5%
4186 2511 100%
Total events 52 40
Heterogeneity: χ2 = 4.81, df = 3( P = 0.19 38%
Test for overall eﬀect: Z = 0.78 (P = 0.43)
0.85 [0.56, 1.28]
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours paclitaxel
Everolimus Paclitaxel
Weight
Total (95% CI)
); I2 =
(a)
0.5 [0.33,  0.76]
0.46 [0.14, 1.51]
0.57 [0.31, 1.04]
0.63 [0.43, 0.93]
0.56 [0.43, 0.72]
Compare (14) 35 897 68 903 40.9%
Spirit II (13) 7 195 5 67 4.5%
Spirit III (15) 24 629 20 305 16.3%
Spirit IV (16) 60 2458 47 1229 38.4%
4179 2504 100%
Total events 126 140
Heterogeneity: χ2 0.75, df = = 3( P = 0.86); I2 = 0%
Test for overall eﬀect: Z = 4.55 (P<0.00001)
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours paclitaxel
Everolimus Paclitaxel
Weight
Total (95% CI)
(b)
0.39 [0.25, 0.6]
0.72 [0.33, 1.56]
0.68 [0.47, 0.99]
0.75 [0.58, 0.97]
0.64 [0.54, 0.77]
Compare (14) 29 897 72 903 24.9%
Spirit II (5) 23 203 11 73 5.1%
Spirit III (15) 79 636 54 312 22.7%
Spirit IV (16) 163 2458 106 1229 47.3%
4194 2517 100%
Total events 294 243
Heterogeneity: χ2 = 6.78, df = 3( P = 0.08); I2 = 56%
Study or subgroup Events Total Events Total
Odds ratio
M-H, ﬁxed, 95% CI
Odds ratio
M-H, ﬁxed, 95% CI
0.01 0.1 1 10 100
Favours everolimus Favours paclitaxel
Everolimus Paclitaxel
Weight
ﬀect: Z = 4.75 (P<0.00001) Test for overall e
Total (95% CI)
(c)
Figure 3: Odds ratio of (a): cardiac death (b): myocardial infarction and (c): target vessel revascularization associated with everolimus-
eluting stent versus paclitaxel-eluting stent.
3.4. TLR (Ischemia-Driven) and TVR. Regarding ischemia-
driven TLR, EESs were signiﬁcantly more eﬀective compared
to PES with an incidence at all followups of 4.2% compared
to 6.8% (OR: 0.57; CI: 0.46–0.71; P<0.00001). Also, EESs
were signiﬁcantly more eﬀective in the reduction of TVR
(Figure 3(c)). The incidence of TVR at all followups was
7.0% (294 of 4194) among patients treated with the EES and
9.7%(243of2517)amongpatientstreatedwiththePES(OR:
0.64; CI: 0.54–0.77; P<0.00001).
4. Interpretation
This meta-analysis clearly demonstrates that EES compared
with PES reduced the incidence of early, late, and very late
ST by about two-thirds. EES also reduced the incidence of
MI and TVR compared to PES. We did not detect statistically
signiﬁcant diﬀerence in the rate of all cause death and
cardiovascular mortality between EES and PES.
The ﬁnding of increased rates of late ST with ﬁrst
generation DES versus BMS has thought to be a major
limitation of this technology [1]. It would be a signiﬁcant
clinical advance if new generations of DES are able to have
comparable rates of late ST as bare stents with preserved
beneﬁts in terms of restenosis.
While individual randomized trials of EES versus PES
showeddiﬀerencesinprimarilyearlyST(within30days),the
eﬀect on late (31–365 days) and very late ST (>365 days) was
uncertain. EES were developed to improve safety outcomesThrombosis 7
among patients including decreasing the risk of late and very
late ST. Our meta-analysis showing diﬀerential rates of ST
between EES and PES is important especially knowing how
fatal ST can be and knowing that dual-antiplatelet therapy
use has the risk of causing bleeding. Diﬀerent durations
of dual-antiplatelet therapy depending on the type of the
stent used are being assessed [17, 18]. The dual-antiplatelet
therapy study [17] which randomized patients with DES
(diﬀerent DES allowed) and BMS to diﬀerent durations of
dual antiplatelet therapy (12 versus 30 months) ﬁnished
recruiting patients, and its results will help in deﬁning the
optimum duration of treatment that will weigh the risk
against beneﬁt of dual antiplatelet therapy. The risks and
beneﬁts of extending Clopidogrel duration may depend on
the particular DES platform used.
The consistency of the reduction of ST in the individual
trials suggests that this ﬁnding is true. The EES and
PES group were well balanced for baseline characteristics,
peri-procedural and postprocedural antiplatelets and anti-
thrombotic drugs. It has been shown that the Xience V, EES
has a more rapid rate of re-endothelialisation compared to
PES. This ﬁnding may be related to the fact that the Xience
V, EES release approximately 80% of its drug within 30
days and nearly all drug within 4 months [1]. Alternatively,
the diﬀerential rates of ST may be related to diﬀerences in
polymers, strut thickness, stent design, stent durability and
the elution properties of Everolimus. Our knowledge about
EESisrapidlyexpanding,andtherearemanyquestionsyetto
beanswered.Forexample,arecentstudycomparingEESand
PES found that in diabetic patients there were no signiﬁcant
diﬀerencesinsafetyoreﬃcacyoutcomebetweenbothgroups
[19]. Finally, our meta-analysis demonstrated that TVR was
reduced with EES versus PES (7.0% versus 9.7%; OR: 0.64;
CI: 0.54–0.77; P<0.00001) with the number needed to treat
(NNT) of 37 patients. Regarding ST, we found that the NNT
with EES compared with PES in order to prevent one case of
ST is about 63 patients.
5. Limitations
The limitations of the current analysis are ﬁrst, that individ-
ual patient data was not available, and second, the current
dataset is underpowered for the outcome of mortality.
However, the strengths of the analysis are consistent ﬁndings
from the studies, and the large eﬀect size with regards to 60–
70% reduction in ST. Another limitation is that the results
of the meta-analysis are only applicable to the XIENCE
V platform and TAXUS Express and TAXUS Liberte, as
these were the tested platforms in the randomized trials.
Further studies will be needed for other stent platforms
using Everolimus with diﬀerent polymers and stent designs.
Finally, this meta-analysis does not provide a comparison of
EES versus BMS.
6. Conclusion
EES are superior to PES in terms of TVR and reduce the rates
of early, late, and very late ST.
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